Abstract
This article provides an in-depth analysis of the study conducted by Wang et al, which explores hepatic arterial infusion chemotherapy and its synergistic strategies in managing advanced hepatocellular carcinoma (HCC). HCC ranks as the fourth most common cause of cancer-related mortality globally and is frequently associated with portal vein tumor thrombus (PVTT). The approach to managing HCC, particularly when PVTT is present, diverges markedly between Eastern and Western practices. These differences are rooted in variations in epidemiology, etiology, pathology, comorbidities, and prognosis. The paper delves into the diagnosis, classification, and treatment strategies for HCC with PVTT, as well as the evolving role and advancements of hepatic arterial infusion chemotherapy in the therapeutic landscape of HCC.